Annual report pursuant to Section 13 and 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Jan. 11, 2022
Mar. 28, 2019
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2019
Dec. 10, 2015
Renumeration amount     $ 6,000      
Consideration amount $ 657,640   393,776      
First payment owed $ 145,000   70,138      
Attorney's fees     $ 235,886      
Interest rate     10.00%      
Recognized loss on contingency     $ (322,000)      
Stock options grant     10,000      
Term of options     3 years      
Consulting services valued     $ 18,946      
Compensation for services, description     As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month      
common stock, par value     $ 0.001 $ 0.001    
Galligan Subscription and Royalty Agreement [Member]            
Common stock, Shares issued   200,000        
Subscription and Royalty Agreement   $ 3,000,000        
Royality percentage minimum   10.00%        
Royality percentage maximum   15.00%        
Lucido Subscription and Royalty Agreement [Member]            
Royality percentage minimum     10.00%      
Royality percentage maximum     15.00%      
Purchase price     $ 15.00      
Common stock     200,000      
Revenue per share     $ 37.50      
Gross revenue per share     $ 25.00      
Percent of aggregate purchase price     65.00%      
Development and expansion expenses amount     $ 3,000,000      
Option [Member]            
Stock options description     (i) Company shall grant 10,000 incentive Stock Options upon achievement of U.S. $500,000 collected gross revenues, (ii) Company shall grant 20,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $1,000,000 collected gross revenues, (iii) Company shall grant 30,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $1,500,000 collected gross revenues, (iv) Company shall grant 40,000 incentive Stock Options to the Agent under its Stock Option Plan upon achievement of U.S. $2,000,000 collected gross revenues.      
Charles River Laboratories, Inc. [Member]            
Remaining commitment     $ 28,936      
BICX Holding Company LLC [Member]            
Common stock issued upon convertible debt     2,227,575      
Convertible Promissory Note         $ 4,160,000  
Conversion agreement description     Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment.      
Issuance price     $ 2.00      
Amount due to investor     $ 1,138,157      
Board Member [Member]            
Stock options grant     4,000      
Term of options     3 years      
Receive common stock equivalent     $ 5,000      
Consulting services valued     12,428      
Alpine Creek [Member]            
Royalty due     91 $ 91    
Total consideration amount     1,531,926      
Payables to Alpine Creek           $ 1,215,000
Paid to Alpine Creek     $ 1,620,000      
Payable commitment description     On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale. On or about January 1, 2021, Mr. Galligan acquired from Alpine Creek the rights to the royalty agreement by and between the Company and Alpine Creek. As of December 31, 2022 and 2021, there are no payments due      
Payable per treatment sold           $ 100
Profit holding percentage           50.00%
Lucido [Member]            
Common stock, Shares issued   200,000        
common stock, par value     $ 0.001